NCT00508586View on ClinicalTrials.gov

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Metastatic Breast Cancer
Interventions
DRUG

PTC299

PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)

Trial Locations (3)

10016

New York University Clinical Cancer Center, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

46202

Indiana University Simon Cancer Center, Indianapolis

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

PTC Therapeutics

INDUSTRY

NCT00508586 - PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter